LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・BioNTech SE ADR

BioNTech SE ADR

Fechado

SetorSaúde

89.38 1.11

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

87.99

Máximo

91.01

Indicadores-chave
By Trading Economics
Rendimento	-239M -541M
Vendas	-779M 120M
EPS	-1.95
Margem de lucro	-450.381
Funcionários	7,807
EBITDA	-481M -549M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+50.9% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.9B 23B
Abertura anterior	88.27
Fecho anterior	89.38

Sentimento de Notícias

By Acuity

17%

83%

30 / 344 Ranking em Healthcare

BioNTech SE ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mai. de 2026, 18:12 UTC

Ganhos

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 13:54 UTC

Ganhos

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

10 de mar. de 2026, 12:50 UTC

Ganhos

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 de mar. de 2026, 11:18 UTC

Ganhos

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

4 de ago. de 2025, 14:14 UTC

Ganhos

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4 de ago. de 2025, 11:59 UTC

Ganhos

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12 de jun. de 2025, 14:20 UTC

Aquisições, Fusões, Aquisições de Empresas

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 de jun. de 2025, 13:34 UTC

Ações em Alta

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10 de jun. de 2025, 12:18 UTC

Ganhos

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Comparação entre Pares

Variação de preço

BioNTech SE ADR Previsão

Preço-alvo

By TipRanks

50.9% parte superior

Previsão para 12 meses

Média 133.47 USD 50.9%

Máximo 167 USD

Mínimo 94 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para BioNTech SE ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para BioNTech SE ADR - Dist nos últimos 3 meses.

Sentimento

By Acuity

30 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac